lundi 24 juin 2019

Onco Actu du 24 juin 2019


2.5 ETIOLOGIE - GÈNES



U of A researchers discover new genetic link to premenopausal breast cancer [University of Alberta]











3.1.1 PRÉVENTION - TABAC - E-CIGS



San Francisco's E-Cigarette Ban Aims to Goose the FDA [Wired]











4.12 BIOPSIES LIQUIDES



Liquid Biopsy Monitoring, Surveillance Efforts Accelerate Across Cancer Types and Technologies [Genome Web]










4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



Adaptive Biotechnologies Announces Private Payor Coverage of clonoSEQ for Detecting and Monitoring MRD in Patients with Lymphoid Blood Cancers, Expanding Access to Over 140 million People in the United States [Adaptive Biotechnologies]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Dying Cells Push the Mouse Immune System into Killing Tumors [The Scientist]











5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



Beating Keytruda a big task, Exelixis and Roche find [Biopharma Dive]











Exelixis' Late-Stage Melanoma Combination Falls Short in Phase III Trial [BioSpace]











Roche/Exelixis' Cotellic fizzles in pivotal melanoma study [EndPoints]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation [OSE]











5.2 PHARMA



Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma [Epizyme]











5.2.1 PHARMA - PARTENARIATS



Janssen Announces Collaboration with University of California, Berkeley and University of California, San Francisco to Expand Data Science Research in Healthcare [Janssen]











5.2.3 PHARMA - ÉCONOMIE



Merck is on top. Investors worry there's only one way to go. [Biopharma Dive]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Should the FDA speed up or slow down approval of new cancer drugs? [STAT]










5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer [Pfizer]










Green-lighted in Japan, FDA quickly spurns Daiichi Sankyo's flawed application for AML drug [EndPoints]











Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML [Daiichi Sankyo]











FDA declines to approve Daiichi Sankyo's blood cancer treatment [Reuters]











6.1 OBSERVATION



More Evidence of an Inverse Association Between Cancer and Alzheimer Disease [JAMA Network Open]










Cancer Survivors May Have Lower Odds for Dementia [WebMD]











6.7.2 APPLIS



Roche's Genentech targets cancer cells via video game with Tumor Quest [Fierce Pharma]